Exposure | Hand OA progression events | Person-time [years] | Crude HR (95% CI) | Adjusted HR (95% CI)a |
---|---|---|---|---|
Age ≤ 55 years at cohort entry | ||||
csDMARD | 130 | 860.6 | Ref (1.00) | Ref (1.00) |
bDMARD | 31 | 127.4 | 1.36 (0.93–2.00) | 1.49 (1.01–2.21) |
Combination | 87 | 526.8 | 0.94 (0.73–1.22) | 1.01 (0.78–1.33) |
Past-use | 10 | 39.2 | 0.96 (0.41–2.26) | 1.09 (0.51–2.34) |
Never-use | 6 | 111.3 | 0.34 (0.14–0.80) | 0.34 (0.14–0.84) |
Age > 55 years at cohort entry | ||||
csDMARD | 291 | 2025.1 | Ref (1.00) | Ref (1.00) |
bDMARD | 48 | 264.6 | 1.13 (0.86–1.51) | 1.21 (0.90–1.61) |
Combination | 149 | 851.9 | 1.11 (0.92–1.33) | 1.16 (0.96–1.41) |
Past-use | 14 | 89.2 | 0.84 (0.52–1.36) | 0.79 (0.48–1.29) |
Never-use | 17 | 224.6 | 0.62 (0.35–1.10) | 0.68 (0.37–1.25) |
Rheumatoid factor negative at cohort entry | ||||
csDMARD | 132 | 1014.4 | Ref (1.00) | Ref (1.00) |
bDMARD | 28 | 167.5 | 1.22 (0.83–1.80) | 1.33 (0.90–1.96) |
Combination | 83 | 503.8 | 1.11 (0.85–1.44) | 1.21 (0.92–1.58) |
Past-use | 7 | 35.3 | 1.21 (0.61–2.38) | 1.16 (0.58–2.33) |
Never-use | 6 | 126.8 | 0.42 (0.19–0.92) | 0.45 (0.20–1.03) |
Rheumatoid factor positive at cohort entry | ||||
csDMARD | 284 | 1832.4 | Ref (1.00) | Ref (1.00) |
bDMARD | 45 | 210.7 | 1.20 (0.89–1.60) | 1.40 (1.04–1.89) |
Combination | 139 | 809.4 | 0.99 (0.82–1.21) | 1.09 (0.89–1.32) |
Past-use | 17 | 86.6 | 0.87 (0.52–1.42) | 0.86 (0.55–1.36) |
Never-use | 16 | 186.2 | 0.58 (0.31–1.10) | 0.59 (0.31–1.13) |
Osteoporosis/fracture or osteoporosis treatment (additionally time-varying) | ||||
csDMARD without osteoporosis | 334 | 2342.2 | Ref (1.00) | Ref (1.00) |
csDMARD with osteoporosis | 87 | 543.5 | 0.88 (0.69–1.13) | 0.87 (0.68–1.11) |
bDMARD without osteoporosis | 50 | 226.5 | 1.35 (1.04–1.77) | 1.43 (1.09–1.88) |
bDMARD with osteoporosis | 29 | 165.4 | 1.00 (0.70–1.43) | 1.04 (0.72–1.49) |
Combination therapy without osteoporosis | 165 | 952.5 | 1.06 (0.89–1.27) | 1.13 (0.94–1.35) |
Combination therapy with osteoporosis | 71 | 426.2 | 0.94 (0.75–1.18) | 0.95 (0.76–1.20) |
Never/past-use without osteoporosis | 38 | 390.3 | 0.65 (0.44–0.95) | 0.69 (0.47–1.02) |
Never/past-use with osteoporosis | 9 | 74.0 | 0.68 (0.34–1.37) | 0.66 (0.34–1.29) |
Prednisone treatment (additionally time-varying) | ||||
csDMARD without prednisone | 219 | 1509.1 | 0.79 (0.57–1.08) | 0.72 (0.52–1.00) |
csDMARD with prednisone | 202 | 1376.6 | 0.87 (0.64–1.20) | 0.81 (0.59–1.12) |
bDMARD without prednisone | 38 | 183.8 | Ref (1.00) | Ref (1.00) |
bDMARD with prednisone | 41 | 208.2 | 1.03 (0.69–1.54) | 1.07 (0.72–1.60) |
Combination therapy without prednisone | 128 | 679.8 | 0.90 (0.64–1.25) | 0.88 (0.63–1.22) |
Combination therapy with prednisone | 108 | 699.0 | 0.83 (0.60–1.17) | 0.83 (0.59–1.17) |
Never/past-use without prednisone | 22 | 287.8 | 0.39 (0.23–0.67) | 0.36 (0.21–0.63) |
Never/past-use with prednisone | 25 | 176.5 | 0.90 (0.54–1.47) | 0.87 (0.53–1.45) |